<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-05">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Wed Feb  5 15:18:04 2003" -->
<!-- isoreceived="20030205221804" -->
<!-- sent="Wed, 5 Feb 2003 17:22:50 -0500" -->
<!-- isosent="20030205222250" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLKEJJCJAA.rms2g@virginia.edu" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="005901c2ccb3$d12bb4f0$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Wed Feb 05 2003 - 15:22:50 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2156.html">Nathanael Allison: "Humour, Fantasy and more"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2154.html">Rafal Smigrodzki: "RE: Returning to the list"</a>
<li><strong>In reply to:</strong> <a href="2112.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2162.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2162.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2155">[ date ]</a>
<a href="index.html#2155">[ thread ]</a>
<a href="subject.html#2155">[ subject ]</a>
<a href="author.html#2155">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<p><em>&gt;
</em><br>
<em>&gt; Excuse me? There is EXCELLENT proof that selegiline offers
</em><br>
<em>&gt; neuroprotection in Parkinson's Disease (PD). That is the sole reason
</em><br>
<em>&gt; it is prescribed for the disease, Rafal. It most definitely increases
</em><br>
<em>&gt; life-span in PD patients by protecting dopaminergic neurons.
</em><br>
<p>### Quote any single class A study supporting this claim.
<br>
<p>As a practicing neurologist I can tell you that selegiline is not prescribed
<br>
in our movement disorders clinic, precisely because of the absence of such
<br>
studies, and the results of DATATOP, currently the last word on selegiline
<br>
in PD.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2156.html">Nathanael Allison: "Humour, Fantasy and more"</a>
<li><strong>Previous message:</strong> <a href="2154.html">Rafal Smigrodzki: "RE: Returning to the list"</a>
<li><strong>In reply to:</strong> <a href="2112.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2162.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2162.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2155">[ date ]</a>
<a href="index.html#2155">[ thread ]</a>
<a href="subject.html#2155">[ subject ]</a>
<a href="author.html#2155">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Wed Feb 05 2003 - 15:20:35 MST
</em></small></p>
</body>
</html>
